GlassScriptPhysician profile
Culber M Shotts
NPI 1427011410
$3,495.98
in general payments reported to CMS, 2019-2025
36 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $226 · 2021: $597 · 2022: $352 · 2023: $423 · 2024: $599 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $534.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $492.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $470.40 | 2021-2025 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $291.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $227.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.81 | 2021-2025 | Xifaxan |
| Amgen INC. | $165.26 | 2019-2023 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $126.30 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.22 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $77.80 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $74.38 | 2019-2020 | |
| Allergan, INC. | $61.74 | 2019-2020 | |
| Astellas Pharma US INC | $61.50 | 2021-2024 | Veozah, Myrbetriq |
| Nestle Healthcare Nutrition INC. | $56.06 | 2021-2023 | |
| Tris Pharma INC | $55.97 | 2025 | Dyanavel Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.67 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $51.78 | 2019-2022 | |
| Genentech USA, INC. | $42.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $37.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.13 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.71 | 2022-2023 | Eliquis |
| Lundbeck LLC | $28.18 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $25.37 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $25.08 | 2021-2023 | Mounjaro |
| Medtronic, INC. | $19.93 | 2025 | Inceptiv |
| Eisai INC. | $19.44 | 2021 | |
| Advanced Respiratory, INC | $19.02 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2024 | Dupixent |
| Sumitomo Pharma America, INC. | $16.27 | 2023 | Gemtesa |
| Aimmune Therapeutics, INC. | $16.12 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $15.73 | 2019 | |
| Amarin Pharma, INC. | $15.31 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.95 | 2022 | |
| Boston Scientific Corporation | $12.63 | 2022 | |
| Esperion Therapeutics, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Culber Shotts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.